6/2/2014 11:00:46 AM
TARRYTOWN, N.Y.--(BUSINESS WIRE)--TechnoVax, Inc., a biotechnology developer of novel vaccines, has received a one-year $509,623 SBIR grant from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH). The grant is to support TechnoVax program for the development of an RSV vaccine utilizing its proprietary VLP technology.
Help employers find you! Check out all the jobs and post your resume.
comments powered by